RESUMEN

New genetic tests for adult-onset diseases raise concerns about possible adverse selection in insurance markets. To test for this behavior, we followed 148 cognitively normal people participating in a randomized clinical trial of genetic testing for Alzheimer's disease for one year after risk assessment and Apolipoprotein E (APOE) genotype disclosure. Although no significant differences were found in health, life, or disability insurance purchases, those who tested positive were 5.76 times more likely to have altered their long-term care insurance than those who did not receive APOE genotype disclosure. If genetic testing for Alzheimer's risk assessment becomes common, it could trigger adverse selection in long-term care insurance.

Asunto(s)

Enfermedad de Alzheimer/diagnóstico , Pruebas Genéticas , Seguro de Cuidados a Largo Plazo , Enfermedad de Alzheimer/genética , Apolipoproteínas E/genética , Confidencialidad , Femenino , Pruebas Genéticas/economía , Pruebas Genéticas/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Medición de Riesgo , Estados Unidos